First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
Solomon, B Mok, T Kim, D Wu, Y Nakagawa, K Mekhail, T Felip, E Cappuzzo, F Paolini, J Usari, T
Solomon, B
Mok, T
Kim, D
Wu, Y
Nakagawa, K
Mekhail, T
Felip, E
Cappuzzo, F
Paolini, J
Usari, T
Citations
Altmetric:
Abstract
The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown.
Description
Date
2014-12-04
Publisher
Collections
Keywords
Type
Article
Citation
First-line crizotinib versus chemotherapy in ALK-positive lung cancer. 2014, 371 (23):2167-77 N Engl J Med